Axsome Therapeutics AXSM Change in AR
Change in AR at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsReceivable.
The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Axsome Therapeutics's change in ar.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Axsome Therapeutics's change in AR?
- Axsome Therapeutics (AXSM) reported change in AR of $26.6M in Q1 2026.
- How has Axsome Therapeutics's change in AR changed year-over-year?
- Axsome Therapeutics's change in AR increased by 37.1% year-over-year, from $19.4M to $26.6M.
- What is the long-term trend for Axsome Therapeutics's change in AR?
- Over 2 years (2023 to 2025), Axsome Therapeutics's change in AR has grown at a 21.8% compound annual growth rate (CAGR), from $57.12M to $84.78M.
- What does change in AR mean?
- The net change in money owed to the company by its customers.
- How do you interpret change in AR?
- An increase consumes cash, while a decrease provides a source of cash.
- How does change in AR compare across companies?
- Standard across all industries; biopharma companies typically see fluctuations based on product launch cycles and payer reimbursement timing.